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Abstract
Acupuncture has increasingly been used as an alternative therapy for treatment of Parkinson’s 
disease (PD). However, the efficacy of acupunture for PD still remains unclear. The present study 
was designed to objectively and safely monitor anti-parkinsonian effects of electroacupuncture 
(EA) and brain activity in nonhuman primates modeling human PD. Six middle-aged rhesus 
monkeys were extensively studied by a computerized behavioral testing battery and by 
pharmacological MRI (phMRI) scans with specific dopaminergic drug stimulations. All animals 
were evaluated for behavior and phMRI responses under normal, parkinsonian, parkinsonian with 
EA treatment and parkinsonian after EA treatment conditions. Stable parkinsonian features were 
observed in all animals prior to entering the EA study and positive responses to levodopa (L-dopa) 
challenge were also seen in all animals. The results demonstrated that chronic EA treatments could 
significantly improve the movement speed and the fine motor performance time during the period 
of EA treatments, and the effectiveness of EA could be detected even 3 months after the EA 
treatment. The phMRI data revealed that chronic EA treatments could alter neuronal activity in the 
striatum, primary motor cortex (M1), cingulate gyrus and global pallidus externa (GPe) in the 
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ipsilateral hemisphere to MPTP lesions. As seen in the changes of parkinsonian features, the 
residual effects of phMRI responses to apomorphine (APO) challenge could also be found in the 
aforementioned areas. The results strongly suggest that anti-parkinsonian effects of EA can be 
objectively assessed, and the method used in the present study could be translated into the human 
clinic with some minor modifications.
Keywords
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1. Introduction
Acupuncture has been gaining popularity for treatment of various disorders as an alternative 
therapy and has been used for years for treatments from lower back pain to stroke and from 
osteoarthritis to Parkinson’s disease (PD) (Rajendran, Thompson et al. 2001, Shulman, Wen 
et al. 2002, Lee, Lyu et al. 2007, Lee, Shin et al. 2008, Lei, Toosizadeh et al. 2016). Despite 
the widespread use of acupuncture in recent years, its efficacy remains largely unclear due to 
a skeptical attitude on how acupuncture works, especially within the framework of Western 
Medicine, methodological flaws, and a lack of high quality studies using objective outcome 
measures (Lee, Shin et al. 2008). To date, the clinical outcomes of acupuncture are assessed 
by empirical observations rather than by objective and quality analysis (Shulman, Wen et al. 
2002, Lee, Shin et al. 2008, Lei, Toosizadeh et al. 2016).
The recent rapid advances in functional magnetic resonance imaging (fMRI) to map global 
and/or target specific bran regions have shown great promise and could be extremely helpful 
for acupuncture studies in human subjects if combined with other subjective measurements 
(Jia, Yu et al. 2012). Pharmacological MRI (phMRI) using dopaminergic drug challenges 
and/or fMRI techniques can provide a means to noninvasively and safely monitor brain 
activity in PD patients and in animals modeling human PD. In clinical studies on PD 
patients, acute acupuncture stimulations at GB34 can activate the putamen and the primary 
motor cortex, and these activations induced by acupuncture were correlated with patient self-
reported improvements of finger-tapping (Chae, Lee et al. 2009). In preclinical studies of PD 
monkeys, phMRI has been successfully used to monitor therapeutic effects (Luan, Ding et 
al. 2008) and as a tool to differentiate dysfunction in basal ganglia between parkinsonian and 
aged monkeys (Andersen, Hardy et al. 2015). Those clinical and preclinical studies 
demonstrate that these imaging modalities have the possibility to untangle the underlying 
neural mechanisms of acupuncture.
Parkinson’s disease has been well characterized by a massive loss of dopamine neurons in 
the substantia nigra (SN). However, clinical symptoms of PD are not manifested until the 
loss of dopamine neurons exceeds a critical threshold, i.e., approximately 50% of those 
neurons having undergone degeneration with an 80% reduction in striatal dopamine levels 
(Bernheimer, Birkmayer et al. 1973). Because dopamine plays a pivotal role in PD, great 
efforts have been made to non-invasively visualize functional changes of the central 
dopamine system in a living brain by using various neuroimaging techniques such as 
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phMRI, especially in preclinical settings (Zhang, Andersen et al. 2000, Zhang, Andersen et 
al. 2006, Andersen, Hardy et al. 2015). Results from those preclinical studies in 
parkinsonian monkeys suggest that phMRI could be used for assessing nigrostriatal 
dysfunction, monitoring treatments and differentiating from age-associated motor 
dysfunctions (Zhang, Andersen et al. 2006, Luan, Ding et al. 2008, Andersen, Hardy et al. 
2015).
The present study was designed to test the hypothesis that therapeutic effectiveness of EA 
can be objectively and quantitatively measured by a computerized behavioral testing battery 
and by phMRI scans with specific dopaminergic drug stimulations. It is worth noticing the 
advantages of using nonhuman primates (NHPs) in EA studies because NHPs not only share 
the most anatomical and physiological features with humans under normal conditions but 
also share behavioral and neuropathological features with humans under parkinsonian 
conditions (Emborg 2007, Johnston and Fox 2015). In the present study, all animals were 
studied under the following physiological stages: normal, hemiparkinsonian, 
hemiparkinsonian with EA treatments and hemiparkinsonian post EA treatments. The results 
from the current study will help us to better understand “where” EA-induced alternations of 
neural activity occur in the brain and “how” the dopamine system gets involved.
2. Results
2.1. General observations
All animals used in the study were readily adapted to the customized vertical chair designed 
for acupuncture procedures after 4–6 weeks of extensive training. With similar outcomes as 
previously reported (Zhao, Fan et al. 2010), all animals tolerated the initial acupuncture and 
subsequent EA procedures well. Discomfort signs including rising of eyebrows, constant 
body movement and physical resistance occurred only occasionally and disappeared after 
properly re-adjusted the amplitude. During the initial chair and acupuncture training periods, 
physical conditions such as body weight, appetite, and cage activity were closely monitored 
in all monkeys by experienced veterinary, husbandry or research staff. No behavioral or 
other abnormalities were reported.
2.2. Behavior
As shown in Figure 1 (closed bars), significantly deceased movement speed (A), and home 
cage activity (B), and longer performance time of the affected hand (C) were found 
following MPTP administration. The movement speed and fine motor performance time 
were markedly improved by the chronic EA treatment (Fig. 1A & C). The movement speed 
and fine motor performance time were virtually returned back to pre-MPTP levels. The cage 
activity was increased but did not reach statistically significant levels due to larger variance 
(Fig. 1B, bars with oblique lines). The fine motor performance time was still improving one 
month post EA treatment (Fig. 1C, bars with crossed lines). In addition, all animals 
responded positively to levodopa challenge evident by a 261% increase of home-cage 
activity measured via Actical counts.
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2.3. phMRI scans
Comparing with the normal stage, profound APO-induced activations were found in all 
measured ROIs (Figs. 2 & 3, Table 1). The differences between normal and post MPTP 
phases in response to apomorphine challenge were highly significant (P<0.001), especially 
in the caudate nucleus, putamen, M1, cingulate gyrus and GPe. In contrast, BOLD responses 
in the pre-motor areas and GPi were not significantly different (Table 1). Those findings 
were in line with previous findings (Zhang, Andersen et al. 2006) that profound APO-
induced activations were seen in the striatum after animals became parkinsonian. In addition 
to those responses described above, APO-induced activations were also observed in the 
MPTP-lesioned primary motor cortex (M1) and cingulate gyrus (Fig. 3, Table 1).
The chronic EA treatment apparently altered neuronal activities in some examined areas 
such as the caudate nucleus, putamen, M1, cingulate gyrus and GPe in which strong APO-
evoked activations were seen after MPTP lesions but significantly reduced after the EA 
treatment. In some cases, the BOLD activations were back to near the levels seen in the 
normal stage (Figs. 2 & 3, Table 1). However, the pharmacological responses were relatively 
mild in the pre-motor cortex and GPi (Table 1). As shown in Figures 2 & 3, the most 
affected regions were the caudate nucleus and primary motor cortex. For example, the APO-
induced activations were reduced more than 5-fold in the caudate nucleus and 4 times in 
primary motor cortex, respectively. Interestingly, residual effects could be found three 
months after the last EA treatment in the caudate nucleus, putamen, M1, cingulate gyrus 
regions judged by comparing the values of BOLD-activations between MPTP+EA and 
MPTP+PEA. A significant difference (P<0.05) between MPTP+EA and MPTP+PEA was 
also seen in the GPe as well (Table 1).
3. Discussion
The primary findings demonstrate that chronic EA at ST36 and LI4 can improve locomotor 
and fine motor functions analyzed by an objective behavioral test battery and can partially 
normalize APO-induced BOLD activations, which were caused by dopamine depletion in 
the cortico-nigro-striatal system in the hemisphere on the ipsilateral side of MPTP-lesions. 
In detail, the profound APO-evoked activations were significantly attenuated after the 3-
month chronic EA treatments, and the BOLD activations were down to near pre-MPTP 
(normal) levels in some ROIs. BOLD-signal changes produced by the 3-month EA 
treatments were accompanied by improvements in motor functions, which were objectively 
measured by computerized behavioral testing apparatus. The overall outcome of the present 
study suggests that the clinical effects of acupuncture can be objectively detected, measured 
and quantitatively analyzed.
The first noticeable effect associated with the chronic EA treatments was the improvement 
of daily physical activity including the significant increase of movement speed detected by 
an automatic video tracking system, and the up-trend improvement of home-cage activity 
measured by a computerized Actical accelerometer. Previous NHP studies have 
demonstrated that the movement speed and home cage activity could be good indicators for 
functional improvements of the central dopamine system in parkinsonian and aged animals 
(Grondin, Zhang et al. 2002, Maswood, Young et al. 2004, Grondin, Zhang et al. 2008, 
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Luan, Ding et al. 2008). In similar settings for an acupuncture study in parkinsonian rhesus 
monkeys, Zhao et al. reported a greater than 3-fold increases of movement speed after 3-
month EA treatments at acupoint ST36 (Zhao, Fan et al. 2010). Interestingly, the movement 
speed measured in parkinsonian monkeys after the 3-month chronic EA treatments was 
comparable to what was seen in either the normal age-matched controls or to their pre-
MPTP levels in this study. The behavioral data suggest that cumulative effects of EA could 
exist and may produce behavioral changes in those parkinsonian animals. In addition, the 
behavioral result was in agreement with our previous published studies (Grondin, Zhang et 
al. 2002, Grondin, Zhang et al. 2008, Luan, Ding et al. 2008). For example, steady 
improvements of movement speed were found in association with increases of striatal 
dopamine in parkinsonian monkeys with chronic intraputamenal GDNF (a dopaminergic 
neurotrophic factor) treatments in those aforementioned studies (Grondin, Zhang et al. 2002) 
and neurturin (Grondin, Zhang et al. 2008).
The automated monkey movement analysis panel (mMAP) for fine movement has been 
increasingly used in preclinical studies in NHPs since it was first described. Studies have 
demonstrated the link between performance time on the mMAP and functional status of the 
basal ganglia (Zhang, Andersen et al. 2000). Improved performance time on mMAP was 
found in all animals after chronic EA treatments in the current study which could reflect 
functional changes in the nigrostriatal system. Grondin et al. reported that the fine motor 
performance times of aged animal were significantly improved, which corresponded to a 
significant increase of dopamine in the caudate nucleus, putamen and substantia nigra by 
more than 100% (Grondin, Cass et al. 2003). In a recent review article, Leem concluded that 
EA could improved the motor symptoms and quality of sleep and depression in PD patients, 
and hypothesized that elevated nitric oxide levels may be a possible mechanism (Leem 
2016). Zeng and Zhao also reported that acupuncture either manual or electroacupuncture 
stimulation at specific acupoints relieved some motor symptoms in patients with Parkinson’s 
and markedly improved many nonmotor symptoms such as psychiatric disorders, sleep 
problems, and gastrointestinal symptoms. When it was used as an adjunct for levodopa, 
acupuncture improved therapeutic efficacy and reduced dosage and the occurrence of side 
effects of levodopa (Zeng and Zhao 2016). Therefore, it would be reasonable to assume that 
the behavioral improvements seen in the present study could also have resulted from 
functional changes in the nigrostriatal dopamine system after the 3-month EA treatments. 
This was also validated by another objective measurement, namely the phMRI in which the 
initial BOLD-activation caused by the MPTP administration was partially normalized by the 
3-month EA treatments in most of the parkinsonian animals.
As mentioned above, significant reductions of APO-evoked BOLD activations were found in 
primary motor cortex and cingulate gyrus, the striatum and GPi on the ipsilateral side of 
MPTP lesions after the 3-month EA treatments. These findings were similar to observations 
with chronic GDNF-induced BOLD responses in parkinsonian brains (Luan, Ding et al. 
2008). In the GDNF study, APO-induced activations were also significantly reduced on the 
side of the MPTP-lesioned putamen where the neurotrophic factor was administered. When 
comparing the two studies, however, the chronic EA treatments produced much broader 
BOLD responses than what was observed in the GDNF study, i.e., EA-induced BOLD 
response were seen not only in the basal ganglia but also in some cortical areas, particularly 
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in the primary motor cortex. Parkinsonian animals used in the study were not treated with 
anti-parkinsonian medication except once for a Levodopa challenge test prior to entry into 
the study. Therefore, these animals could be considered as a de novo drug-naive model of 
human PD. In clinical fMRI studies, hypoactivations of the primary sensorimotor cortex was 
found in de novo Parkinson’s disease (Tessa, Lucetti et al. 2012, Luo, Song et al. 2014). 
Therefore, it is reasonable to assume that EA induced improvements in motor functions 
could be through increases of brain activation, especially in the motor cortex.
Spontaneous recovery rather than chronic EA effects could reasonably be ruled out because 
the animal model used in the study was proven stable and has been used in various previous 
studies (Zhao, Fan et al. 2010), and all monkeys used in this study had expressed stable PD 
features for at least 12 months prior to entering the study. As we previously described (Ding, 
Luan et al. 2008), there are two important factors determining the probability of spontaneous 
recovery, namely route of administration of MPTP and age of the animals. A number of 
studies have demonstrated that the most spontaneous recovery reported in previous 
publications occurs in systemic models including intravenous, intraperitoneal, intramuscular 
and subcutaneous injections (Crossman, Clarke et al. 1987, Schneider, Yuwiler et al. 1987, 
Moratalla, Quinn et al. 1992, Albanese, Granata et al. 1993, Rose, Nomoto et al. 1993). The 
assumption was further supported by another study in which spontaneous behavioral 
recoveries were found in 4 to 6 years old young vervet monkeys after receiving multiple 
intramuscular injections of MPTP (Mounayar, Boulet et al. 2007). Animals used in this 
study were at least 15 years old with the unilateral administration of the MPTP via the 
carotid artery infusion, which were the key factors for maintaining stabilities of PD features 
seen in those animals. Overall, results of the present study support the assumption that 
chronic EA at ST36 and LI4 could alleviate PD symptoms through modulate brain activity, 
although a separate control group rather than animals used as their own controls as in this 
study will be needed to better confirm EA’s role in improvements of PD features and 
alternation of brain functions in future studies.
Many of the acupoints such as LI4, ST36, GB34, LV3 that have been widely used in the 
treatment of PD were also used in fMRI studies (Dhond, Kettner et al. 2007). The result 
from some fMRI studies in PD patients suggests that therapeutic acupuncture could 
modulate activity in some cortical and subcortical areas. For example, Chae et al. reported 
that the primary motor cortex and putamen could be activated by acute acupunctures at 
GB34, and the acupuncture-induced BOLD activations were correlated with improvements 
in motor function compared with placebo-treated patients (Wu, Hsieh et al. 1999, Chae, Lee 
et al. 2009). These fMRI studies shed lights on how to interpret acupuncture-induced 
functional improvements in PD patients and whether the EA treatment can induce real 
changes in the parkinsonian brains. The phMRI results from the present study strongly 
indicate that APO-evoked BOLD activations were significantly reduced by chronic EA 
treatment to a level near the pre-MPTP stage in primary motor cortex, cingulate gyrus and 
striatum only on the ipsilateral side of MPTP lesions. This observation supports the notion 
that chronic EA treatments could alter brain activity and connectivity in some cortical and 
subcortical regions, and/or functional status of the endogenous dopaminergic 
neurotransmission. This assumption has been supported by a few fMRI and microdialysis 
studies in both animal models and humans. For example, EA could alter fMRI signals and 
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dopamine release in parkinsonian rats (Chen, Wang et al. 2008, Qin, Tian et al. 2008). 
However, more studies are needed to further prove the assumption.
So far, the present study demonstrates that effects of anti-parkinsonian EA treatments can be 
objectively and quantitatively assessed in nonhuman primates which model human PD. The 
methods used in this study could be practically translated into the human clinic with some 
minor modifications because 1) EA was performed under fully consciousness conditions, 2) 
the clinical MRI scanner and imaging sequences are regularly used in the clinic, and 3) all 
drugs and particularly the APO used in the study are already proved by the FDA for 
treatment of PD. Nevertheless, caution must be taken on how to interpret the animal’s data 
for clinical use. The differences are obvious between EA treatments in PD patients and PD 
NHPs. First, all animals are treated equally regarding living conditions, medications and 
even severity of parkinsonisms. Second, among challenges in acupuncture studies in 
humans, the biggest issue apparently has been the lack of an adequate placebo in accessing 
the effectiveness of acupuncture. For obvious reasons, placebo effects are a less concerning 
issue in NHP studies. Nevertheless, it would be helpful for assessing EA therapeutic effects 
to add an additional group of animals in future studies. There are several other limitations of 
the present study are needed to addressed in future preclinical studies: 1) only female 
animals were used in the present study in concerns of reducing individual sexual variance, 
animals, animals handling issues and availability. Both male and female animals should be 
studies because sex-related differences in clinical manifestations and consequences of 
Parkinson’s disease have been poorly explored (Farhadi, Vosoughi et al. 2017); 2) limited 
number of animals used in the study, which sacrificed the statistical power; and 3) all phMRI 
scans were performed under light anesthetized conditions due to artifacts generated from 
head motion. Considering the possibilities of mild effects of the chronic EA treatment, 
motion artifacts could significantly confound the result (Zhang, Andersen et al. 2000). 
Therefore light anesthesia was utilized during all phMRI scans for this study. All limitations 
should be carefully addressed in future studies and make this kind translational studies 
become more clinical relevant.
4. Experimental procedures
4.1. Animals
Six female rhesus monkeys (Macaca mulatta) ranging in age from 15–18 years old and 
weighing 6.2–8.6 kg were used in the study. All animals were housed in individual cages 
with water available ad libitum. Standard primate biscuits were supplemented daily with 
fresh fruit and vegetables. All animals underwent four phases: normal, hemiparkinsonian, 
hemiparkinsonian with EA treatments and hemiparkinsonian post EA treatments. In detail, 
each animal received the following procedures: unilateral MPTP administration, training for 
EA, one phMRI scan with apomorphine (APO) challenge under each phase, behavioral tests 
and EA treatments. Based on previously published procedures by our group, a neurotoxin 
MPTP (0.12 mg/kg) was unilaterally administered through the right carotid artery under 
sterile conditions to produce stable, moderate parkinsonian features seen in PD on the 
contralateral side of the body to MPTP administration. All procedures were conducted in the 
Laboratory Animal Facilities of the University of Kentucky, which are fully accredited by 
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the Association for Assessment and Accreditation of Laboratory Animal Care International. 
The animals’ care was supervised by experienced veterinarians and all protocols used in the 
study were approved by the University of Kentucky’s Animal Care and Use Committee 
following NIH and USDA guidelines.
4.2. Animal training for EA
Detailed training procedures and depiction of the restraint apparatus used for EA have been 
previously described elsewhere (Zhao, Fan et al. 2010). In brief, animals were introduced to 
the specially designed vertical restraint chair used to help control the animal’s movement 
and to have easy access to those acupoints used in the study for EA. As previously described 
(Zhao, Fan et al. 2010), a custom designed and manufactured vertical restraint chair with 
dimensions (25cm x 69cm x 28cm) was made primarily of acrylic, which permits the 
monitoring of arm and leg movement due to its transparent feature. During each training 
session, animals are allowed to watch nature based television programs and are having 
preferred foods such as peanuts to minimize feelings of anxiety. All training sessions were 
taking place in the same room and were repeated 2–3 times per week until all animals were 
completely comfortable with the entire process.
4.3. Behavioral evaluation
All animals were extensively monitored and evaluated by non-biased, objective, and non-
invasive methods including 1) an automated video-tracking system (EthoVision Pro, Noldus 
Technologies, Asheville, NC); 2) Actical accelerometers (MiniMitter, Bend, OR); 3) 
movement analysis panel (mMAP) for upper fine motor function.
All animals were videotaped before, during and after chronic, weekly EA treatments. The 
monkeys were transferred into a customized videotaping cage in the morning of the day of 
testing. The videotapes (DVDs) were analyzed for movement speed. The home-cage activity 
levels were measured by using previously published methods, i.e., an Actical accelerometer 
mounted on a collar worn by the animal, and activity counts per minute were recorded 24/7. 
Upper limb motor function was evaluated pre and post-EA using a task consisting of 
retrieving miniature marsh mallows from an automated receptacle chamber attached to the 
home cage. Motor performance was electronically recorded over 12 trials as the time (to 
within 10 ms) for the animal to retrieve the food from a platform in the receptacle chamber 
(Zhang, Andersen et al. 2000).
Before entering EA studies and approximately 2 years after the MPTP treatment, all animals 
were challenged with levodopa, which it is the “gold” standard for treatment of PD in 
humans, to see if they positively responded to the dopaminergic stimulation. Each animal 
received an intramuscular injection of levodopa-methyl ester (75 mg Sigma Co.) and 
carbidopa (7.5 mg, Sigma Co.) mixed separately in sterile saline. Responsiveness to 
levodopa was judged by home-cage activity measured by Actical accelerometers.
4.4. Electroacupunctural procedures
Following our previously established standard procedures (Zhao, Fan et al. 2010), animals 
were introduced to acupuncture after extensive chair training. To familiarize the animal with 
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the procedures, acupuncture needles were administered for 2–3 trials, each lasting 
approximately 30 min. The acupoints selected for this study were based on a previous study 
(Zhao, Fan et al. 2010) and included: 1) HeGu (LI4), which lies halfway between the middle 
of metacarpal bone I and the middle of metacarpal bone II, i.e., on the dorsum of the hand, 
between the 1st and 2nd metacarpal bones and on the midpoint of the radial of the 2nd 
metacarpal bone in the hand (Fig. 1B); and 2) Zu San Li (ST36), which lies on the 
anteriolateral side of the leg, one finger breadth (middle finger) from the anterior crest of the 
tibia in the leg (Fig. 1C). The acupuncture areas were shaven and cleaned with alcohol 
before the needle was inserted. The stainless-steel acupuncture needles used in the study 
were 0.18 mm in diameter and 20 mm in length. Electro-stimulations were supplied by using 
Acupuncture Stimulator model 808II (AA Health Device, Tempe, AZ). Bi-directional 
square-wave electrical pulses (0.2 ms duration, 100 Hz) were administered for 
approximately 30 minutes per EA treatment. The amplitude level was 3 mA at the beginning 
and then increased gradually to 4 to 5 mA. The animal was closely monitored by multiple 
video cameras. Discomfort was expressed by raised eyebrows or by withdrawal reflex or 
verbal expression. All animals received 3 EA treatment sessions per week for 12 weeks.
4.5. phMRI protocols including BOLD activations
All animals were scanned on a Siemens 3.0T TIM Trio clinical MRI system while the 
animals were under light general anesthesia (~1% Isoflurane). Images were acquired using a 
custom designed six-channel phased array monkey head receiver coil. The BOLD-effect 
weighted MR images used to measure the phMRI response were acquired in an anatomically 
coronal plane. The image planes of the acquisition were arranged to cover the motor cortex 
and the basal ganglia. A segmented gradient-echo EPI sequence with TE=28 ms and a turbo 
factor of 7 was used to reduce echo train length and minimize susceptibility-related artifacts. 
The EPI sequence acquisition parameters are FOV=112x98 mm and image matrix 64x56 for 
an in-plane resolution of 1.75 mm. A total of 15 contiguous slices, each 2 mm thick, were 
acquired at a rate of 15 s per EPI volume. The overall scan duration was 80 minutes with 
128 volumes acquired prior to APO administration as a baseline and 192 after APO to track 
the response. Images were motion corrected and spatially smoothed using a Gaussian kernel 
of width 3.5 mm. The phMRI response was calculated as the fractional signal change in % 
of the average of the post-APO image data relative to the pre-APO baseline. A co-registered 
high-resolution (0.67×0.67×1 mm) T1-weighted anatomical MRI scan was acquired in each 
session for spatial localization of the activation response.
4.6. Statistical analysis
The data were analyzed using Prism software, version 6. One-way ANOVA was followed by 
Bonferroni’s multiple comparison tests. P-values ≤0.05 were considered significant. The 
results are presented as the mean ± the standard error of the mean.
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Abbreviations
APO apomorphine
BOLD blood oxygen level dependent
EA electroacupuncture
fMRI functional magnetic resonance imaging
GDNF glial cell derived neurotrophic factor
GPe global pallidus externa
mMAP monkey movement analysis panel
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NHP nonhuman primate
PD Parkinson’s disease
phMRI pharmacological MRI
ROI region of interest
SN substantia nigra
References
Albanese A, Granata R, Gregori B, Piccardi MP, Colosimo C, Tonali P. Chronic administration of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and 
biochemical correlates. Neuroscience. 1993; 55(3):823–832. [PubMed: 8105418] 
Andersen AH, Hardy PA, Forman E, Gerhardt GA, Gash DM, Grondin RC, Zhang Z. Pharmacologic 
MRI (phMRI) as a tool to differentiate Parkinson’s disease-related from age-related changes in 
basal ganglia function. Neurobiol Aging. 2015; 36(2):1174–1182. [PubMed: 25443764] 
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the 
syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J 
Neurol Sci. 1973; 20(4):415–455. [PubMed: 4272516] 
Chae Y, Lee H, Kim H, Kim CH, Chang DI, Kim KM, Park HJ. Parsing brain activity associated with 
acupuncture treatment in Parkinson’s diseases. Mov Disord. 2009; 24(12):1794–1802. [PubMed: 
19533753] 
Chen YI, Wang FN, Nelson AJ, Xu H, Kim Y, Rosen BR, Kwong KK. Electrical stimulation 
modulates the amphetamine-induced hemodynamic changes: an fMRI study to compare the effect 
of stimulating locations and frequencies on rats. Neurosci Lett. 2008; 444(2):117–121. [PubMed: 
18722508] 
Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA. MPTP-induced parkinsonism in 
the monkey: neurochemical pathology, complications of treatment and pathophysiological 
mechanisms. Can J Neurol Sci. 1987; 14(3 Suppl):428–435. [PubMed: 3119180] 
Dhond RP, Kettner N, Napadow V. Neuroimaging acupuncture effects in the human brain. J Altern 
Complement Med. 2007; 13(6):603–616. [PubMed: 17718643] 
Ding F, Luan L, Ai Y, Walton A, Gerhardt GA, Gash DM, Grondin R, Zhang Z. Development of a 
stable, early stage unilateral model of Parkinson’s disease in middle-aged rhesus monkeys. Exp 
Neurol. 2008; 212(2):431–439. [PubMed: 18547564] 
Zhang et al. Page 10
Brain Res. Author manuscript; available in PMC 2019 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Emborg ME. Nonhuman primate models of Parkinson’s disease. Ilar j. 2007; 48(4):339–355. 
[PubMed: 17712221] 
Farhadi F, Vosoughi K, Shahidi GA, Delbari A, Lokk J, Fereshtehnejad SM. Sexual dimorphism in 
Parkinson’s disease: differences in clinical manifestations, quality of life and psychosocial 
functioning between males and females. Neuropsychiatr Dis Treat. 2017; 13:329–338. [PubMed: 
28203083] 
Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, Gerhardt GA. Glial cell line-derived 
neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus 
monkeys. J Neurosci. 2003; 23(5):1974–1980. [PubMed: 12629203] 
Grondin R, Zhang Z, Ai Y, Ding F, Walton AA, Surgener SP, Gerhardt GA, Gash DM. Intraputamenal 
infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus 
pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant. 2008; 17(4):373–381. [PubMed: 
18522240] 
Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, Elsberry DD, Klein MC, Gerhardt 
GA, Gash DM. Chronic, controlled GDNF infusion promotes structural and functional recovery in 
advanced parkinsonian monkeys. Brain. 2002; 125(Pt 10):2191–2201. [PubMed: 12244077] 
Jia J, Yu Y, Deng JH, Robinson N, Bovey M, Cui YH, Liu HR, Ding W, Wu HG, Wang XM. A review 
of Omics research in acupuncture: the relevance and future prospects for understanding the nature 
of meridians and acupoints. J Ethnopharmacol. 2012; 140(3):594–603. [PubMed: 22322253] 
Johnston TM, Fox SH. Symptomatic Models of Parkinson’s Disease and L-DOPA-Induced Dyskinesia 
in Non-human Primates. Curr Top Behav Neurosci. 2015; 22:221–235. [PubMed: 25158623] 
Lee MS, Shin BC, Kong JC, Ernst E. Effectiveness of acupuncture for Parkinson’s disease: a 
systematic review. Mov Disord. 2008; 23(11):1505–1515. [PubMed: 18618661] 
Lee SJ, Lyu YS, Kang HW, Sohn IC, Koo S, Kim MS, Park BR, Song JH, Kim JH. Antinociception of 
heterotopic electro-acupuncture mediated by the dorsolateral funiculus. Am J Chin Med. 2007; 
35(2):251–264. [PubMed: 17436366] 
Leem J. Acupuncture for motor symptom improvement in Parkinson’s disease and the potential 
identification of responders to acupuncture treatment. Integr Med Res. 2016; 5(4):332–335. 
[PubMed: 28462136] 
Lei H, Toosizadeh N, Schwenk M, Sherman S, Karp S, Sternberg E, Najafi B. A Pilot Clinical Trial to 
Objectively Assess the Efficacy of Electroacupuncture on Gait in Patients with Parkinson’s 
Disease Using Body Worn Sensors. PLoS One. 2016; 11(5):e0155613. [PubMed: 27227460] 
Luan L, Ding F, Ai Y, Andersen A, Hardy P, Forman E, Gerhardt GA, Gash DM, Grondin R, Zhang Z. 
Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys. 
Cell Transplant. 2008; 17(4):417–425. [PubMed: 18522244] 
Luo C, Song W, Chen Q, Zheng Z, Chen K, Cao B, Yang J, Li J, Huang X, Gong Q, Shang HF. 
Reduced functional connectivity in early-stage drug-naive Parkinson’s disease: a resting-state 
fMRI study. Neurobiol Aging. 2014; 35(2):431–441. [PubMed: 24074808] 
Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, Grondin R, Roth GS, Mattison J, 
Lane MA, Carson RE, Cohen RM, Mouton PR, Quigley C, Mattson MP, Ingram DK. Caloric 
restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral 
deficits in a primate model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2004; 101(52):
18171–18176. [PubMed: 15604149] 
Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW, Graybiel AM. Differential vulnerability of 
primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-
methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci U S A. 1992; 89(9):3859–3863. 
[PubMed: 1570304] 
Mounayar S, Boulet S, Tande D, Jan C, Pessiglione M, Hirsch EC, Feger J, Savasta M, Francois C, 
Tremblay L. A new model to study compensatory mechanisms in MPTP-treated monkeys 
exhibiting recovery. Brain. 2007; 130(Pt 11):2898–2914. [PubMed: 17855373] 
Qin W, Tian J, Bai L, Pan X, Yang L, Chen P, Dai J, Ai L, Zhao B, Gong Q, Wang W, von Deneen 
KM, Liu Y. FMRI connectivity analysis of acupuncture effects on an amygdala-associated brain 
network. Mol Pain. 2008; 4:55. [PubMed: 19014532] 
Zhang et al. Page 11
Brain Res. Author manuscript; available in PMC 2019 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson’s 
disease. Neurology. 2001; 57(5):790–794. [PubMed: 11552005] 
Rose S, Nomoto M, Jackson EA, Gibb WR, Jaehnig P, Jenner P, Marsden CD. Age-related effects of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol. 
1993; 230(2):177–185. [PubMed: 8422900] 
Schneider JS, Yuwiler A, Markham CH. Selective loss of subpopulations of ventral mesencephalic 
dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 1987; 411(1):144–
150. [PubMed: 2886180] 
Shulman LM, Wen X, Weiner WJ, Bateman D, Minagar A, Duncan R, Konefal J. Acupuncture therapy 
for the symptoms of Parkinson’s disease. Mov Disord. 2002; 17(4):799–802. [PubMed: 12210879] 
Tessa C, Lucetti C, Diciotti S, Paoli L, Cecchi P, Giannelli M, Baldacci F, Ginestroni A, Vignali C, 
Mascalchi M, Bonuccelli U. Hypoactivation of the primary sensorimotor cortex in de novo 
Parkinson’s disease : a motor fMRI study under controlled conditions. Neuroradiology. 2012; 
54(3):261–268. [PubMed: 21927866] 
Wu MT, Hsieh JC, Xiong J, Yang CF, Pan HB, Chen YC, Tsai G, Rosen BR, Kwong KK. Central 
nervous pathway for acupuncture stimulation: localization of processing with functional MR 
imaging of the brain--preliminary experience. Radiology. 1999; 212(1):133–141. [PubMed: 
10405732] 
Zeng BY, Zhao K. Effect of Acupuncture on the Motor and Nonmotor Symptoms in Parkinson’s 
Disease--A Review of Clinical Studies. CNS Neurosci Ther. 2016; 22(5):333–341. [PubMed: 
26843036] 
Zhang Z, Andersen A, Smith C, Grondin R, Gerhardt G, Gash D. Motor slowing and parkinsonian 
signs in aging rhesus monkeys mirror human aging. J Gerontol A Biol Sci Med Sci. 2000; 
55(10):B473–480. [PubMed: 11034220] 
Zhang Z, Andersen AH, Ai Y, Loveland A, Hardy PA, Gerhardt GA, Gash DM. Assessing nigrostriatal 
dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage. 2006; 
33(2):636–643. [PubMed: 16949305] 
Zhao F, Fan X, Grondin R, Edwards R, Forman E, Moorehead J, Gerhardt G, Wang X, Zhang Z. 
Improved methods for electroacupuncture and electromyographic recordings in normal and 
parkinsonian rhesus monkeys. J Neurosci Methods. 2010; 192(2):199–206. [PubMed: 20654649] 
Zhang et al. Page 12
Brain Res. Author manuscript; available in PMC 2019 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Highlights
1. Chronic EA treatment improves movement speed and fine motor performance 
time.
2. Anti-parkinsonian effects of EA can be objectively assessed.
3. The method used in the present study could be translated into the human 
clinic.
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Figure 1. 
Behavior changes of animals following different treatments. Movement speed (A), home 
cage activity (B) and fine motor performance time changes (C) following MPTP 
administration, chronic EA treatment or post EA treatment.
a, P<0.05 compared with normal; b, P<0.05 compared with MPTP; c, P<0.05 compared with 
MPTP+EA.
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Figure 2. 
phMRI activation changes of animals following different treatments. phMRI activation 
changes of Caudate Nucleus (A) and Putamen (B) following MPTP administration, chronic 
EA treatment or post EA treatment.
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Figure 3. 
phMRI activation changes of Primary Motor Cortex following MPTP administration, 
chronic EA treatment or post EA treatment.
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Table 1
BOLD-responses in some cortical and subcortical areas
Cingulate GPe GPi
ROIs
Normal 0.74±0.25 −0.27±0.3 −0.16±0.26
MPTP 2.16±0.09a 1.92±0.13a 0.84±0.41
MPTP + EA 0.58±0.23b 0.54±0.19d,e 0.44±0.31
MPTP + PEA 0.85±0.11c 0.69±0.09f 1.11±0.14d
GPe, globus pallidus externa; GPi, globus pallidus interna; ROIs, region of interest;
a
P<0.001 vs. normal;
b
P<0.001 vs. MPTP;
c
P<0.001 vs. MPTP+EA,
d
P<0.05 vs. normal;
e
P<0.01 vs. MPTP;
f
P<0.05 vs. MPTP+EA,
EA, elecgtroacupuncture; PEA, post elecroacupuncture.
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